Bicara Therapeutics Inc.

US$8.65As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:BCAXHealthcare
Country USA
PE (Fwd) •••
TSR 2Y CAGR (40.13%)
Div yield —
ROE (41.01%)
Biotechnology
Beta (5Y) (0.34)
PE TTM —
TSR TTM (46.77%)
Mkt cap US$572.4M
ROIC (27.83%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$10
18.99%
(40.07%)
Sell 2|3|8|12|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.10
0.10
0.11
0.12
13.92%
4.42%
19.97%
21.89%
Revenue$M
50.96
49.85
49.59
51.07
12.33%
3.72%
(2.00%)
3.90%
Peers (US$572.4M)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.588
(0.988)
(0.631)
EBIT/Intx
0.881
0.160
0.195
Own earn%
23.45
19.66
22.25
Sh yield%
42.72
22.94
22.34
Owners
Insiders/Inst%
0.16
20.27
Short interest%
1.94
SBC / revenue%
0.26
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
16–25
$1 testx
0.0
Incr. ROIC%
1